Researchers developed a novel gene signature that has prognostic value in patients with multiple myeloma who are treated with immunomodulatory derivatives. READ MORE
Recent research has uncovered a non-inferior, cost-effective alternative to standard therapy for autologous stem cell mobilization in multiple myeloma. The study’s author discusses his findings.
Clinicians are now trying to treat multiple myeloma similar to leukemia.
Carol Ann Huff, MD, discusses how to best use newly-approved therapies for multiple myeloma.
Comparing autologous stem cell transplant with bortezomib, melphalan, and prednisone.
Effect of Route of Bortezomib Administration on Treatment Outcomes in Previously Untreated Patients with Multiple Myeloma: A Retrospective Analysis from US Community Oncology Practices
Researchers tested Bortezomib Administration on Treatment Outcomes in patients with myeloma.
Researchers developed a novel gene signature that has prognostic value in patients with multiple myeloma who are treated with immunomodulatory derivatives.
Patients with relapsed or refractory multiple myeloma should be given individualized treatment based on numerous factors, including biology of the disease and type of relapse.
Results of eight recent clinical trials show that older patients treated for relapsed or refractory multiple myeloma with novel therapies had similar rates of progression-free survival as younger patients.
Daratumumab-based combination therapies are ineffective in patients with multiple myeloma who have been heavily pre-treated or are refractory to one or more agents in a DCT.
Research in Review
A recent cost-effectiveness analysis compared novel agents and chemotherapy for older Medicare patients with multiple myeloma.
According to recent research presented at ASCO, adding which targeting agent to standard of care carfilzomib, lenalidomide, and dexamethasone is a safe and efficacious alternative to ASCT for patients with multiple myeloma?
Targeted therapy against a particular protein has the potential to improve outcomes and fracture-free survival for patients with multiple myeloma.
Adult patients with multiple myeloma who receive a high-dose chemotherapy regimen plus autologous stem-cell transplantation improve their median progression-free survival by 14 months compared with patients who receive chemotherapy alone.